Julian Kött

ORCID: 0000-0003-2073-3909
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Dermatology and Skin Diseases
  • Cutaneous Melanoma Detection and Management
  • Cutaneous lymphoproliferative disorders research
  • Medicine and Dermatology Studies History
  • Cancer Genomics and Diagnostics
  • CAR-T cell therapy research
  • Lymphoma Diagnosis and Treatment
  • Hair Growth and Disorders
  • Immune Cell Function and Interaction
  • Ocular Oncology and Treatments
  • Melanoma and MAPK Pathways
  • Dermatological diseases and infestations
  • Immune cells in cancer
  • Dermatologic Treatments and Research
  • Autoimmune Bullous Skin Diseases
  • S100 Proteins and Annexins
  • Allergic Rhinitis and Sensitization
  • Nail Diseases and Treatments
  • Cancer Diagnosis and Treatment
  • Nonmelanoma Skin Cancer Studies
  • Poxvirus research and outbreaks
  • Ferroptosis and cancer prognosis
  • Brain Metastases and Treatment

University Medical Center Hamburg-Eppendorf
2021-2025

Universität Hamburg
2021-2025

University Cancer Center Hamburg
2022-2024

Klinik und Poliklinik für Neurologie
2023-2024

Eppendorf (Germany)
2023

Martini-Klinik
2022

Highlights•Drugs currently used against irAEs reduce anti-tumor immunity•ECP induces adiponectin production in inflamed organs while sparing tumor tissue•ECP high response rates patients with ICI-induced irAEsSummaryImmune-related adverse events (irAEs) cancer receiving immune checkpoint inhibitors (ICIs) cause morbidity and necessitate cessation of treatment. Comparing irAE treatments, we find that immunity is preserved mice after extracorporeal photopheresis (ECP) but reduced...

10.1016/j.ccell.2025.01.004 article EN cc-by Cancer Cell 2025-02-01

The role of Sentinel Lymph Node Biopsy (SLNB) is pivotal in the contemporary staging cutaneous melanoma. In this review, we examine advanced molecular testing platforms like gene expression profiling (GEP) and immunohistochemistry (IHC) as tools for predicting prognosis sentinel lymph nodes. We compare these innovative approaches with traditional assessments. Additionally, delve into shared genetic protein markers between GEP IHC tests their relevance to melanoma biology, exploring...

10.1016/j.ejca.2024.113989 article EN cc-by European Journal of Cancer 2024-03-08

Circulating tumor cells (CTCs) play an important role in metastasis formation. Aberrant signaling of oncogenic pathways (e.g., PI3K/AKT/mTOR pathway) drives progression. In this work, the susceptibility colon cancer CTC-derived cell line CTC-MCC-41 to AKT and mammalian target rapamycin (mTOR) inhibitors was evaluated. Additionally, functional expressed isoforms characterized line. The efficacy inhibitor MK2206, mTOR RAD001, combination examined a murine intracardiac xenotransplantation...

10.1002/1878-0261.70024 article EN cc-by Molecular Oncology 2025-03-25

Immune checkpoint inhibition has revolutionized melanoma therapy, but many patients show primary or secondary resistance. Biomarkers are, therefore, urgently required to predict response prior the initiation of therapy and monitor disease progression. In this prospective study, we analyzed serum C-C motif chemokine ligand 20 (CCL20) concentration using an enzyme-linked immunosorbent assay. Blood was obtained at baseline before immunotherapy with anti-PD-1 monotherapy Nivolumab Ipilimumab in...

10.3390/cancers16091737 article EN Cancers 2024-04-29

Abstract Background The treatment of melanoma has been revolutionized by the use immune checkpoint inhibition (ICI), but many patients do not benefit. Furthermore, immune‐related adverse events may occur during therapy. A predictive biomarker is needed to reliably identify benefitting. In lung, renal cell and bladder cancer early C‐reactive protein (CRP) kinetics were shown be a for ICI. Objective Here, we investigate CRP as ICI in patients. Methods Two independent prospectively collected...

10.1111/jdv.19941 article EN cc-by-nc Journal of the European Academy of Dermatology and Venereology 2024-03-11

Summary Background Interferon‐alpha is an important therapeutic option for the treatment of cutaneous T‐cell lymphomas (CTCL). Since approved recombinant interferon‐α‐2a (IFN‐α2a) has no longer been produced since January 2020, pegylated interferon‐α2a (pegIFN‐α2a) can be used as alternative treatment, even though it not CTCL. The aim this multicentre study was to generate comprehensive data on efficacy and tolerability pegIFN‐α2a in Patients Methods A multicenter retrospective conducted...

10.1111/ddg.15511 article EN cc-by-nc JDDG Journal der Deutschen Dermatologischen Gesellschaft 2024-10-02

Uveal Melanoma (UM) is a rare disease; however, it the most common primary intraocular malignant tumor in adults. Hematogenous metastasis, occurring up to 50% of cases, mainly liver (90%), associated with poor clinical course and treatment failure. In contrast dramatic benefits immunotherapy many entities, as seen cutaneous melanoma, immune checkpoint inhibitors (ICI) do not achieve comparable results Metastatic UM (MUM). The aim this study was investigate whether combination ICI...

10.3390/cancers13246390 article EN Cancers 2021-12-20

Background:There is a high demand for dermatological care in Germany. As use of teledermatology has increased significantly, this study aimed to investigate the impact on patient care. Methods:This retrospective cross-sectional used data from direct-to-consumer platform using store-and-forward technology available Germany between July 2021 and April 2022. Additional characteristics were collected voluntary follow-up questionnaire, 28 days after teleconsultation. Results:Data 1,999 enrolled...

10.1089/tmj.2022.0472 article EN Telemedicine Journal and e-Health 2023-03-02

Oral finasteride and topical minoxidil are the current standard of care for male androgenetic alopecia a combination two treatments can be considered greater efficacy. Clinical trials have also yielded promising results, but routine data lacking.

10.1111/jocd.16360 article EN cc-by Journal of Cosmetic Dermatology 2024-05-07

Abstract Background Adjuvant treatment of stage II–IV melanoma with PD‐1‐based immune checkpoint inhibitors (ICI) has improved relapse‐free survival (RFS) and therefore become a standard‐of‐care option. Approximately 25%–30% patients still recur within 1 year. Predictive biomarkers reflecting real‐world data are desired. The predictive relevance tumour tissue PD‐L1 expression in the adjuvant setting remains inconclusive. Objectives This retrospective, observational study was conducted to...

10.1111/jdv.20177 article EN cc-by-nc Journal of the European Academy of Dermatology and Venereology 2024-06-15

Immune checkpoint inhibition (ICI) has yielded remarkable results in prolonging survival of metastatic melanoma patients but only a subset individuals treated respond to therapy. Success ICI treatment appears depend on the number tumor-infiltrating effector T-cells, which are known be influenced by activated eosinophils. To verify co-occurrence eosinophils and T-cells melanoma, immunofluorescence was performed 285 primary or tumor tissue specimens from 118 patients. Moreover, eosinophil...

10.3390/cancers14225676 article EN Cancers 2022-11-18

The number of online prescription platforms (OPPs) offering telemedical diagnosis and treatment, including finasteride, for androgenetic alopecia (AA) by using medical questionnaires (MQs) has increased. This type care delivery differs completely from traditional forms. study aimed to investigate a potential paradigm shift in AA treatment measuring the extent traffic generated OPPs that exclusively treat furthermore characterizing sociodemographic features men undergoing finasteride an OPP...

10.2147/ccid.s400614 article EN cc-by-nc Clinical Cosmetic and Investigational Dermatology 2023-04-01

Background: Adherence to dermatological treatment is described as poor. Empathy and open communication in the physician–patient relationship has been proven improve adherence. As direct-to-consumer teledermatology enables patients access consultations without in-person interactions, we hypothesized adherence be low. Methods: The objective of study was examine teledermatology. This retrospective cross-sectional used data from treated through a German platform between July 2021 April 2022....

10.1089/tmj.2022.0290 article EN Telemedicine Journal and e-Health 2022-12-08

Summary Background and Objectives Skin diseases are a common reason for consultations in pediatric practice. The present study aims to characterize the dermatological requests of resident specialists using teledermatology Germany. Patients Methods This analysis consultation requests, submitted by pediatricians designated dermatologist via telemedical system ( PädExpert) store‐and‐forward technology, was performed between February 2021 December 2021. Results included 504 requests. mean age...

10.1111/ddg.14979 article EN cc-by-nc JDDG Journal der Deutschen Dermatologischen Gesellschaft 2023-02-01
Coming Soon ...